Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big week for Endologix

This article was originally published in The Gray Sheet

Executive Summary

The abdominal aortic aneurysm stent graft maker said Oct. 15 it is reviewing an unsolicited acquisition bid worth about $98 million, or $2.25 per share, from hedge fund Elliott Associates. Endologix said it will "make a determination and respond in due course." Two days later, the firm announced FDA approval of its PMA supplement for the Powerlink XL stent graft system, applicable for wider aortic necks that its currently available Powerlink product. The new graft is approved for proximal aortic necks measuring between 23 and 32 millimeters. Endologix's share price started the week at $1.33 and closed on Oct. 17 at $1.96
Advertisement

Related Content

Endologix rebuffs takeover bid
Advertisement
UsernamePublicRestriction

Register

MT026684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel